The atmosphere was electric as I settled into my seat at the SDPA Annual Summer Dermatology Conference in San Diego. Marc Serota, MD, a triple board-certified expert in Dermatology, Allergy/Immunology, and Pediatrics, was about to present on chronic urticaria. As a PA, I was eager to absorb every detail.
Dr. Serota began by defining chronic spontaneous urticaria (CSU) – those pesky, itchy hives that persist for over six weeks. I found myself nodding along, recalling patients whose lives had been disrupted by this condition. The statistic that CSU affects 1% of the U.S. population really hit home.
As he delved into the pathophysiology, I was fascinated by the central role of mast cells. The image of these tiny cellular powerhouses releasing histamine and causing such widespread symptoms was vivid in my mind.
Coverage: SDPA Annual Summer Dermatology Conference, June 5-9, 2024, in San Diego, California
The discussion on lab work was particularly enlightening. Dr. Serota emphasized that while we often order numerous tests, they rarely lead to significant findings. This reminder to be judicious in our testing approach was invaluable.
I was intrigued by the concept of chronic autoimmune urticaria. The idea that 30-50% of chronic urticaria cases might be linked to autoimmunity opened up new avenues for understanding and potentially treating this condition.
The treatment guidelines presented were a game-changer. Starting with high-dose second-generation antihistamines and progressing to omalizumab if needed seemed like a solid, evidence-based approach. I made a mental note to review my current treatment protocols.
But what really got me excited were the emerging therapies. Dupilumab showing promise in clinical trials, and remibrutinib, a novel BTK inhibitor, demonstrating significant symptom reduction – these advancements could revolutionize how we manage CSU.
As I left the conference hall, my mind was buzzing with new information and possibilities. I felt reinvigorated in my role as a PA, armed with cutting-edge knowledge to better serve my patients with chronic urticaria. The future of dermatology looks brighter than ever, and I’m thrilled to be part of this evolving field.
Byline: Michael Rubio, MPAS, PA-C
Pictured: Marc Serota, MD